² Vassar R, Bennet BD, Babu-Khan et al. Beta secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.

³ Strittmatter WJ, Saunders A.M, Schmechel D, et al. Apolipoprotein E: High-Avidity Binding to Beta-Amyloid and Increased Frequency of Type 4 Allele in Late-Onset Familial Alzheimer Disease. Proc Natl Acad Sci 1993; 90:1977-1981.

⁴ Corder EH, Saunders AM, Strittmatter WJ. Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families. Science 1993;261:921-923.

5 Bennett C, Crawford F, Osborne A. et al. Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's disease but is not causative. Am J Genet 1995;60:1-6.

⁶American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on Use of Apolipoprotein E Testing for Alzheimer Disease. JAMA 1995. 274(20):1627-1629.

⁷ Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999 Jun;38(6):735-67.

⁸ Winblad B. Poritis N. Memantine in severe dementia: Results of the M-9-BEST study . International Journal of Geriatric Psychiatry 1999;14(2):135-146.

Recommended Reading

Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000 May 1;21(3):383-421.

Wolozin B, Behl . Mechanisms of Neurodegenerative Disorders Part 1: Protein Aggregates. Arch Neurol 2000. Vol 57, No 6, pp 769-908.

Wolozin B, Behl C. Mechanisms of Neurodegenerative Disorders Part 2: Control of Cell Death. Arch Neurol 2000. Vol 57, No 6, pp 769-908.